80
Participants
Start Date
May 27, 2025
Primary Completion Date
June 10, 2028
Study Completion Date
September 10, 2028
Ruxolitinib
IBM patients treated by ruxolitinib (JAKAVI®), 15mg per os, twice a day, during 12 months.
Placebo
IBM patients treated by placebo, twice a day, during 12 months.
NOT_YET_RECRUITING
Hôpital de la Timone, APHM, Marseille
ACTIVE_NOT_RECRUITING
CHU Caen Normandie, Caen
NOT_YET_RECRUITING
Hôpital Pierre-Paul Riquet, CHU de Toulouse, Toulouse
ACTIVE_NOT_RECRUITING
Hôpital Pellegrin - Tripode, CHU de Bordeaux, Bordeaux
ACTIVE_NOT_RECRUITING
Hôpital Bellevue, CHU Saint-Etienne, Saint-Etienne
NOT_YET_RECRUITING
Hôtel-Dieu, CHU Nantes, Nantes
ACTIVE_NOT_RECRUITING
Hôpital Christian Cabrol, CHU Reims, Reims
ACTIVE_NOT_RECRUITING
CHU Nancy, Nancy
NOT_YET_RECRUITING
Hôpital Roger Salengro, CHU de Lille, Lille
NOT_YET_RECRUITING
Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg
ACTIVE_NOT_RECRUITING
Hôpital Pierre Wertheimer, CHU de Lyon, Bron
ACTIVE_NOT_RECRUITING
Hôpital Pitié-Salpêtrière, APHP, Paris
ACTIVE_NOT_RECRUITING
Hôpital Dupuytren, CHU de Limoges, Limoges
ACTIVE_NOT_RECRUITING
Hôpital Raymond Poincaré, APHP, Garches
RECRUITING
Hôpital Henri-Mondor, APHP, Créteil
RECRUITING
Hôpital Pasteur, CHU de Nice, Nice
Assistance Publique - Hôpitaux de Paris
OTHER